Nerlynx (neratinib) — United Healthcare

Initial criteria

• Diagnosis of breast cancer AND Patient has brain metastases AND Disease is HER2-positive AND Used in combination with capecitabine or paclitaxel

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Nerlynx therapy

Approval duration

12 months